Pacific Biosciences Of California (PACB) Operating Margin (2010 - 2026)
Pacific Biosciences Of California's quarterly Operating Margin came in at 22.48% in Q1 2026, up 113203.0% year-on-year from N/an in Q1 2025, and up 75.64% quarter-over-quarter from 92.28% in Q4 2025.
Pacific Biosciences Of California has reported Operating Margin for 17 years, with the latest figure at 22.48% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin rose 113203.0% year-over-year to 22.48%; the trailing twelve-month figure through Mar 2026 stood at 83.29% (up 45616.0% YoY), and the FY2025 full-year result was 346.15%, down 3818.0% from the prior year.
- Operating Margin for Q1 2026 stood at 22.48%, up from 92.28% in the prior quarter.
- The five-year high for Operating Margin was 22.48% in Q1 2026, with the low at 1154.51% in Q1 2025.
- Average Operating Margin over 5 years is 258.4%, with a median of 191.64% recorded in 2022.
- Year-over-year, Operating Margin plunged 94487 bps in 2025 and surged 113203 bps in 2026.
- Tracing PACB's Operating Margin over 5 years: stood at 318.37% in 2022, then soared by 53 bps to 150.02% in 2023, then plunged by 160 bps to 390.14% in 2024, then jumped by 76 bps to 92.28% in 2025, then surged by 76 bps to 22.48% in 2026.
- The last three Operating Margin figures came in at 22.48% (Q1 2026), 92.28% (Q4 2025), and 101.13% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 6.17% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 19.94% |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn | -22.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.48% |
| Dec 31, 2025 | -92.28% |
| Sep 30, 2025 | -101.13% |
| Jun 30, 2025 | -112.79% |
| Mar 31, 2025 | -1,154.51% |
| Dec 31, 2024 | -390.14% |
| Sep 30, 2024 | -160.32% |
| Jun 30, 2024 | -488.28% |
| Mar 31, 2024 | -209.64% |
| Dec 31, 2023 | -150.02% |
| Sep 30, 2023 | -148.12% |
| Jun 30, 2023 | -153.82% |
| Mar 31, 2023 | -234.58% |
| Dec 31, 2022 | -318.37% |
| Sep 30, 2022 | -230.94% |
| Jun 30, 2022 | -191.64% |
| Mar 31, 2022 | -233.69% |
| Dec 31, 2021 | -179.56% |
| Jun 30, 2021 | -122.75% |
| Mar 31, 2021 | -116.25% |
| Dec 31, 2020 | -88.36% |
| Sep 30, 2020 | -126.69% |
| Jun 30, 2020 | -137.75% |
| Mar 31, 2020 | -209.70% |
| Dec 31, 2019 | -64.15% |
| Sep 30, 2019 | -128.29% |
| Jun 30, 2019 | -99.02% |
| Mar 31, 2019 | -183.46% |
| Dec 31, 2018 | -156.83% |
| Sep 30, 2018 | -135.85% |
| Jun 30, 2018 | -100.77% |
| Mar 31, 2018 | -123.69% |
| Dec 31, 2017 | -82.33% |
| Sep 30, 2017 | -91.61% |
| Jun 30, 2017 | -121.49% |
| Mar 31, 2017 | -93.51% |
| Dec 31, 2016 | -69.49% |
| Sep 30, 2016 | -66.63% |
| Jun 30, 2016 | -87.10% |
| Mar 31, 2016 | -97.06% |
| Dec 31, 2015 | -2.93% |
| Sep 30, 2015 | 18.78% |
| Jun 30, 2015 | -45.54% |
| Mar 31, 2015 | -109.54% |
| Dec 31, 2014 | -105.86% |
| Sep 30, 2014 | -40.79% |
| Jun 30, 2014 | -160.19% |
| Mar 31, 2014 | -156.72% |
| Dec 31, 2013 | -186.16% |
| Sep 30, 2013 | -268.63% |
| Jun 30, 2013 | -330.64% |
| Mar 31, 2013 | -369.43% |
| Dec 31, 2012 | -369.07% |
| Sep 30, 2012 | -813.36% |
| Jun 30, 2012 | -309.35% |
| Mar 31, 2012 | -274.06% |
| Dec 31, 2011 | -68.47% |
| Sep 30, 2011 | -299.80% |
| Jun 30, 2011 | -11,803.65% |
| Mar 31, 2011 | -12,950.74% |
| Dec 31, 2010 | -13,067.50% |
| Sep 30, 2010 | -18,498.18% |
| Jun 30, 2010 | -5,194.75% |